{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:42:47Z","timestamp":1791294167466,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270635"],"award-info":[{"award-number":["81270635"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370633"],"award-info":[{"award-number":["81370633"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.bbrc.2014.03.086","type":"journal-article","created":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T15:55:36Z","timestamp":1395849336000},"page":"1204-1210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells"],"prefix":"10.1016","volume":"446","author":[{"given":"Houcai","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2014.03.086_b0005","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.03.086_b0010","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbrc.2014.03.086_b0015","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1007\/s002800100310","article-title":"ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy","volume":"48","author":"Mauro","year":"2001","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2014.03.086_b0020","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2014.03.086_b0025","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2002-02-0545","article-title":"Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses","volume":"101","author":"Kantarjian","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.03.086_b0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.leukres.2003.08.002","article-title":"Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase","volume":"28","author":"Moravcova","year":"2004","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bbrc.2014.03.086_b0035","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.03.086_b0040","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbrc.2014.03.086_b0045","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2014.03.086_b0050","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.03.086_b0055","first-page":"337","article-title":"Establishment of an imatinib resistant cell line K562\/G01 and its characterization","volume":"25","author":"Qi","year":"2004","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bbrc.2014.03.086_b0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2014.03.086_b0065","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.03.086_b0070","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/338438a0","article-title":"Identification of the long ubiquitin extension as ribosomal protein S27a","volume":"338","author":"Redman","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2014.03.086_b0075","doi-asserted-by":"crossref","first-page":"523","DOI":"10.4161\/cc.9.3.11152","article-title":"Degradation of ubiquitin: the fate of the cellular reaper","volume":"9","author":"Shabek","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2014.03.086_b0080","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrm2731","article-title":"Breaking the chains: structure and function of the deubiquitinases","volume":"10","author":"Komander","year":"2009","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2014.03.086_b0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/bjc.1992.12","article-title":"Differential expression of translation-associated genes in benign and malignant human breast tumours","volume":"65","author":"Adams","year":"1992","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2014.03.086_b0090","first-page":"1916","article-title":"Ubiquitin-ribosomal protein S27a gene overexpressed in human colorectal carcinoma is an early growth response gene","volume":"53","author":"Wong","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2014.03.086_b0095","first-page":"6677","article-title":"Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells","volume":"51","author":"Kanayama","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2014.03.086_b0100","doi-asserted-by":"crossref","first-page":"22730","DOI":"10.1074\/jbc.M111.223651","article-title":"Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress","volume":"286","author":"Sun","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2014.03.086_b0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molcel.2009.03.006","article-title":"How common are extraribosomal functions of ribosomal proteins?","volume":"34","author":"Warner","year":"2009","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bbrc.2014.03.086_b0110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/0968-0004(96)20011-8","article-title":"Extraribosomal functions of ribosomal proteins","volume":"21","author":"Wool","year":"1996","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.bbrc.2014.03.086_b0115","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V97.7.1999","article-title":"In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents","volume":"97","author":"Kano","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2014.03.086_b0120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/leu.2010.238","article-title":"Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia","volume":"25","author":"Bixby","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2014.03.086_b0125","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.leu.2403998","article-title":"The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance","volume":"20","author":"Cilloni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2014.03.086_b0130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.2174\/187152009788451851","article-title":"The PI3K\/Akt pathway as a target in the treatment of hematologic malignancies","volume":"9","author":"Kawauchi","year":"2009","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.bbrc.2014.03.086_b0135","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1146\/annurev.cb.04.110188.001103","article-title":"Mitochondrial membrane potential in living cells","volume":"4","author":"Chen","year":"1988","journal-title":"Annu. Rev. Cell Biol."},{"key":"10.1016\/j.bbrc.2014.03.086_b0140","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1258\/ebm.2012.011423","article-title":"Raf\/MEK\/ERK signaling inhibition enhances the ability of dequalinium to induce apoptosis in the human leukemic cell line K562","volume":"237","author":"Sancho","year":"2012","journal-title":"Exp. Biol. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1400535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1400535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T21:30:51Z","timestamp":1597613451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1400535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0006291X1400535X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.03.086","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2014.03.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}